Introducing our pancreatic cancer segment model.
At IVRS AB we are constantly working on ways to expand our service array with robust and clinically relevant methods. We are thus proud to introduce a series of segment models, starting with our platform to validate drug candidates targeting pancreatic cancer.
Our approach to a successful validatory study combines orthotopic transplantation of PDX/CDX with in vivo bioluminescence imaging and molecular analysis, all done under the same roof by us!
Download the segment model on human pancreatic cancer here.
Curious to know how we can help you on the next validatory step in your preclinical pipeline? Reach out to us at info@ivrs.se!
